Literature DB >> 30812049

Review of Health Problems in Adult Patients with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Nicole Reisch1.   

Abstract

The introduction of newborn screening programmes in most Western countries for classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) enables timely introduction of life-saving glucocorticoid replacement in affected babies. Early diagnosis and optimised pediatric care not only successfully led to survival but also allow that almost all patients reach adulthood. Cohort studies in adults, however, provided evidence for significant health problems and co-morbidities of adult patients such as life-threatening adrenal crises, cardiovascular and metabolic health problems, fertility problems, benign endocrine tumours, and osteopenia and osteoporosis. This review summarises the current state of knowledge aiming to emphasize the neccessity of primary and secondary prevention of additional long-term health issues as a major task of health professionals in the care of CAH. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2019        PMID: 30812049     DOI: 10.1055/a-0820-2085

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  6 in total

Review 1.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

2.  Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.

Authors:  Richard J Auchus; Kyriakie Sarafoglou; Patricia Y Fechner; Maria G Vogiatzi; Erik A Imel; Shanlee M Davis; Nagdeep Giri; Julia Sturgeon; Eiry Roberts; Jean L Chan; Robert H Farber
Journal:  J Clin Endocrinol Metab       Date:  2022-02-17       Impact factor: 5.958

Review 3.  Novel treatments for congenital adrenal hyperplasia.

Authors:  Mariska A M Schröder; Hedi L Claahsen-van der Grinten
Journal:  Rev Endocr Metab Disord       Date:  2022-02-23       Impact factor: 9.306

4.  Body Image and Quality of Life in Women with Congenital Adrenal Hyperplasia.

Authors:  Lea Tschaidse; Marcus Quinkler; Hedi Claahsen-van der Grinten; Anna Nordenström; Aude De Brac de la Perriere; Matthias K Auer; Nicole Reisch
Journal:  J Clin Med       Date:  2022-08-02       Impact factor: 4.964

5.  Syrian females with congenital adrenal hyperplasia: a case series.

Authors:  Nada Dehneh; Rami Jarjour; Sahar Idelbi; Assad Alibrahem; Sahar Al Fahoum
Journal:  J Med Case Rep       Date:  2022-10-15

6.  Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.

Authors:  Kyriakie Sarafoglou; Chris N Barnes; Michael Huang; Erik A Imel; Ivy-Joan Madu; Deborah P Merke; David Moriarty; Samer Nakhle; Ron S Newfield; Maria G Vogiatzi; Richard J Auchus
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.